These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15353425)

  • 41. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
    Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
    Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.
    Young JB; Abraham WT; Smith AL; Leon AR; Lieberman R; Wilkoff B; Canby RC; Schroeder JS; Liem LB; Hall S; Wheelan K;
    JAMA; 2003 May; 289(20):2685-94. PubMed ID: 12771115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
    Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic assessment of cardiac resynchronization therapy.
    Callejo D; Guerra M; Hernández-Madrid A; Blasco JA
    Rev Esp Cardiol; 2010 Nov; 63(11):1235-43. PubMed ID: 21070719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction?
    Bond M; Mealing S; Anderson R; Dean J; Stein K; Taylor RS
    Int J Cardiol; 2009 Nov; 137(3):206-15. PubMed ID: 18703244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
    Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost effectiveness of biventricular pacemakers in heart failure patients.
    Heerey A; Lauer M; Alsolaiman F; Czerr J; James K
    Am J Cardiovasc Drugs; 2006; 6(2):129-37. PubMed ID: 16555866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
    Stylopoulos N; Gazelle GS; Rattner DW
    Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure.
    Modi RM; Liu CL; Isaza N; Raber I; Calvachi P; Zimetbaum P; Bellows BK; Kramer DB; Kazi DS
    Circ Cardiovasc Qual Outcomes; 2022 Mar; 15(3):e008443. PubMed ID: 35105176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
    Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
    Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain.
    Almenar L; Díaz B; Quesada A; Crespo C; Martí B; Mealing S; Linde C; Daubert C
    Int J Technol Assess Health Care; 2013 Apr; 29(2):140-6. PubMed ID: 23552131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.
    Biton Y; Kutyifa V; Cygankiewicz I; Goldenberg I; Klein H; McNitt S; Polonsky B; Ruwald AC; Ruwald MH; Moss AJ; Zareba W
    Circ Heart Fail; 2016 Feb; 9(2):e002667. PubMed ID: 26823498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
    Catherwood E; Fitzpatrick WD; Greenberg ML; Holzberger PT; Malenka DJ; Gerling BR; Birkmeyer JD
    Ann Intern Med; 1999 Apr; 130(8):625-36. PubMed ID: 10215558
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential cost-effectiveness of public access defibrillation in the United States.
    Nichol G; Hallstrom AP; Ornato JP; Riegel B; Stiell IG; Valenzuela T; Wells GA; White RD; Weisfeldt ML
    Circulation; 1998 Apr; 97(13):1315-20. PubMed ID: 9570205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
    Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.